A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Nephropathies
- Endocrine System Diseases
- Glomerulonephritis
- Glomerulosclerosis, Focal Segmental
- Kidney Diseases
- Nephritis
- Nephrosis
- Nephrosis, Lipoid
- Urologic Diseases
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Multiple-ascending, placebo-controlledMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Approximately 125 patients will be enrolled in this study across the United States. Patients with DN and FSGS/TR-MCD will be randomized in 3 ascending dose cohorts to receive either GFB-887 or placebo.
Approximately 125 patients will be enrolled in this study across the United States. Patients with DN and FSGS/TR-MCD will be randomized in 3 ascending dose cohorts to receive either GFB-887 or placebo.
Tracking Information
- NCT #
- NCT04387448
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon